Regeneron Announces Upcoming 2013 Investor Conference Presentations - FOX 8 WVUE New Orleans News, Weather, Sports

Regeneron Announces Upcoming 2013 Investor Conference Presentations

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Regeneron Pharmaceuticals, Inc.

TARRYTOWN, N.Y., May 8, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations at the following investor conferences:

• UBS Global Healthcare Conference on Monday, May 20, 2013.  The presentation is scheduled for 10:00 a.m. Eastern Time.
• 38^th Annual dbAccess Healthcare Conference on Wednesday, May 29, 2013.  The presentation is scheduled for 8:40 a.m. Eastern Time.
• Jefferies 2013 Healthcare Conference on June 3, 2013.  The presentation is scheduled for 9:00 a.m. Eastern Time.
• Goldman Sachs 34^th Annual Global Healthcare Conference on Tuesday, June 11, 2013.  The presentation is scheduled for 11:40 a.m. Eastern Time (8:40 a.m. Pacific Time).

The presentations may be accessed through the Company's web site, www.regeneron.com, on the 'Events and Presentations' page.  An archived version of the presentations will be available for 30 days.

About Regeneron Pharmaceuticals, Inc.
Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, allergic asthma and atopic dermatitis.  For additional information about the company, please visit www.regeneron.com.

©2012 PR Newswire. All Rights Reserved.